- Home
- CANF vs UGRO Comparison
CANF vs UGRO Comparison
Compare CANF & UGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- UGRO
- Stock Information
- Founded
- CANF 1994
- UGRO 2014
- Country
- CANF Israel
- UGRO United States
- Employees
- CANF N/A
- UGRO N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- UGRO Industrial Specialties
- Sector
- CANF Health Care
- UGRO Consumer Discretionary
- Exchange
- CANF Nasdaq
- UGRO Nasdaq
- Market Cap
- CANF 14.4M
- UGRO 18.0M
- IPO Year
- CANF N/A
- UGRO N/A
- Fundamental
- Price
- CANF $2.37
- UGRO $1.44
- Analyst Decision
- CANF Strong Buy
- UGRO Strong Buy
- Analyst Count
- CANF 2
- UGRO 2
- Target Price
- CANF $14.00
- UGRO $5.63
- AVG Volume (30 Days)
- CANF 136.1K
- UGRO 21.1K
- Earning Date
- CANF 11-15-2024
- UGRO 11-07-2024
- Dividend Yield
- CANF N/A
- UGRO N/A
- EPS Growth
- CANF N/A
- UGRO N/A
- EPS
- CANF N/A
- UGRO N/A
- Revenue
- CANF $667,000.00
- UGRO $70,320,066.00
- Revenue This Year
- CANF $356.93
- UGRO $14.76
- Revenue Next Year
- CANF N/A
- UGRO $21.29
- P/E Ratio
- CANF N/A
- UGRO N/A
- Revenue Growth
- CANF N/A
- UGRO 12.08
- 52 Week Low
- CANF $1.81
- UGRO $1.02
- 52 Week High
- CANF $4.69
- UGRO $2.84
- Technical
- Relative Strength Index (RSI)
- CANF 56.81
- UGRO 52.67
- Support Level
- CANF $1.87
- UGRO $1.34
- Resistance Level
- CANF $2.55
- UGRO $1.55
- Average True Range (ATR)
- CANF 0.16
- UGRO 0.09
- MACD
- CANF 0.05
- UGRO 0.01
- Stochastic Oscillator
- CANF 60.94
- UGRO 60.79
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.